生物
维管菌
微生物群
失调
微生物学
长双歧杆菌
肠道菌群
双歧杆菌
免疫学
细菌
食品科学
发酵
链球菌
乳酸菌
生物信息学
遗传学
作者
Julie E. Button,Casey M. Cosetta,Abigail L. Reens,Sarah L Brooker,Aislinn D. Rowan-Nash,Richard Lavin,Russell Saur,Shuning Zheng,Chloe Autran,Martin L. Lee,Adam K. Sun,Amin M. Alousi,Christine B. Peterson,Andrew Y. Koh,David J. Rechtman,Robert R. Jenq,Gregory J. McKenzie
标识
DOI:10.1016/j.chom.2023.08.004
摘要
Manipulation of the gut microbiome using live biotherapeutic products shows promise for clinical applications but remains challenging to achieve. Here, we induced dysbiosis in 56 healthy volunteers using antibiotics to test a synbiotic comprising the infant gut microbe, Bifidobacterium longum subspecies infantis (B. infantis), and human milk oligosaccharides (HMOs). B. infantis engrafted in 76% of subjects in an HMO-dependent manner, reaching a relative abundance of up to 81%. Changes in microbiome composition and gut metabolites reflect altered recovery of engrafted subjects compared with controls. Engraftment associates with increases in lactate-consuming Veillonella, faster acetate recovery, and changes in indolelactate and p-cresol sulfate, metabolites that impact host inflammatory status. Furthermore, Veillonella co-cultured in vitro and in vivo with B. infantis and HMO converts lactate produced by B. infantis to propionate, an important mediator of host physiology. These results suggest that the synbiotic reproducibly and predictably modulates recovery of a dysbiotic microbiome.
科研通智能强力驱动
Strongly Powered by AbleSci AI